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Patients with Graves’ hyperthyroidism (GH) treated with a combination of thyrostatic drugs and T4, i.e., block and replacement
therapy(BRT),oftenreportbodyweight(BW)gain.WeaimedtodeterminechangesinBWandenergymetabolismuponcessation
ofBRTinthesepatients,andtoidentifypossibleendocrinedeterminants.Weanalysed22patientswithGH(i)duringBRT,and(ii)
12 weeks after BRT cessation. Patients were euthyroid at both visits. There were no diﬀerences in BW or resting energy expenditure
(REE) between visits. At visit 1, after 13.5 (9.5–48.0) months of BRT, serum free (F)T4 correlated positively with REE (r = 0.433,
P = 0.044) and negatively with body fat % (r =− 0.450, P = 0.035). Plasma FT3 and FT3/FT4 ratio showed an increase 12w
after cessation of BRT (20%, P<0.0001 and 16%, P = 0.007, resp.). Moreover, the relative change in FT3/FT4 ratio showed
a signiﬁcant, positive correlation with the relative change in REE between the 2 visits (r = 0.465, P = 0.029). In conclusion,
serum FT4 determines REE in euthyroid patients with GH treated with BRT. Twelve weeks after BRT cessation, BW and energy
homeostasis are unaltered. However, as serum FT3/FT4 ratio increases after cessation of BRT, which is a positive determinant of
changes in REE, a longer term BW decrease is likely to occur.
1.Introduction
Patients with a ﬁrst episode of Graves’ hyperthyroidism
(GH) are often treated initially with pharmacological ther-
apy. Many clinicians use a therapeutic regimen commonly
referred to as “block and replacement therapy” (BRT) to
attain biochemical euthyroidism. This involves the admin-
istration of a thyroid-hormone- (TH-) synthesis-blocking
agent such as methimazole (MMI) or propylthiouracil
(PTU) to which L-thyroxine (T4) is added once serum TH
concentrations reach the euthyroid range. In other causes
of hyperthyroidism, such as toxic multinodular goiter or
in severe cases of GH, radio-iodine ablation or (partial)
surgical thyroidectomy may be used as an initial means to
block thyroid hormone secretion, often combined with T4
supplementation at a later stage.
Hyperthyroidism is associated with profound changes in
energy homeostasis that usually resolve upon treatment with
BRT. As a result, the weight loss experienced during hyper-
thyroidism is usually regained during treatment. Some older
studies in hyperthyroid subjects have reported no diﬀerence
between premorbid body weight (BW) and BW after one
year of treatment [1, 2], ﬁtting with the notion of tight BW
set-point regulation. However, a more recent study in 162
patients reported a continuing BW gain after treatment for
hyperthyroidism. BW had increased by ∼4kg after 1 year
and increased by up to 10kg after four years of treatment
[3]. In line with this observation, up to 84% of patients2 International Journal of Endocrinology
report weight gain exceeding their premorbid BW following
treatment of hyperthyroidism [4]. Although the etiology
of this excessive weight gain is incompletely understood at
present, some authors have proposed that it may result from
subnormal energy expenditure due to iatrogenic suppression
of TH concentrations to the lower end of the normal range
[1, 5].
It is remarkable that to date studies addressing this
issue have focussed on the comparison between BW and
energy homeostasis in untreated hyperthyroid patients with
the euthyroid situation during BRT. Approximately 50%
of patients with Graves hyperthyroidism remain euthyroid
following cessation of BRT after at least one year of treat-
ment, reﬂecting the remission rate of autoimmune hyper-
thyroidism [6]. In our outpatient clinic of endocrinology,
BRTisdiscontinuedinpatientswithGraveshyperthyroidism
after approximately one year of treatment. This regimen
oﬀers a good opportunity to investigate changes in BW upon
cessation of BRT in euthyroid patients with Graves disease
and to identify determinants of BW and energy metabolism
in this setting.
2.MaterialsandMethods
2.1. Subjects. Patients were recruited from the Outpatient
Clinics of Endocrinology and Metabolism at the Academic
Medical Center of the University of Amsterdam. Inclusion
criteria were (i) a minimum of six months of MMI or
PTU in combination with T4 pharmacotherapy for Graves’
hyperthyroidism, diagnosed on the basis of standard bio-
chemical and scintigraphic criteria [7], (ii) biochemical
euthyroidism (deﬁned as serum free T4 (FT4)b e t w e e n9
and 23pmol/L, serum T3 between 1.3 and 2.7nmol/L and
serum TSH <5mU/L) on both study occasions, and (iii) age
between 20 and 60 years. As low or even suppressed serum
TSH values can be found in euthyroid patients treated for
Graves hyperthyroidism, probably resulting from binding of
circulating TSH receptor (TSH-R) autoantibodies (TBII) to
the TSH-R on the thyrotrophs [8], patients with serum TSH
values below the lower limit of the reference range could
participate in the study.
Exclusion criteria were (i) pregnancy, (ii) abnormal liver
function as apparent from serum alanine-aminotransferase
>45U/L, aspartate-aminotransferase >40U/L or gamma-
glutamyl-transferase >60U/L, and (iii) abnormal kidney
function (serum creatinine >95μmol/L) at inclusion.
The study was approved by the Medical Ethical Com-
mittee of the Academic Medical Center of the University of
Amsterdam and accordingly, written informed consent was
obtained from all subjects prior to inclusion.
2.2. Protocol. In this observational study, the participants
were studied in the morning after an overnight fast on
two occasions, that is, (i) during biochemical euthyroidism
while on BRT (visit 1) and (ii) during biochemical euthy-
roidism, 12 weeks after discontinuation of BRT (indicating
remission of Graves’ hyperthyroidism) (visit 2). At visit 1,
a medical history was obtained regarding premorbid BW,
initial presentation of Graves hyperthyroidism. Data on BW
progression during the course of treatment were obtained
from clinic records for every individual patient. On both
occasions, BW, resting energy expenditure (REE), body
composition, and serum T3,T 4,F T 3,F T 4, reverse T3
(rT3), TSH, insulin, glucose, adrenalin, and noradrenalin
were assessed. All measurements were performed in the
morning between 8.00 and 12.00AM. Of all patients that
were included in the study, one patient used a β-adrenergic
blocker (metoprolol), and one patient used a benzodiazepine
(diazepam).Bothpatientswereinstructednottotakeanyco-
medication within at least 24h prior to study measurements.
All patients were instructed not to take thyroxine in the
morning of visit 1, and smoking was not allowed within 12h
prior to measurements. Patients were instructed to prevent
physical exercise at least 3 days before both study visits,
to eat 3 meals per day, and not to change their eating or
exercise habits between the visits. Importantly, patients were
instructed to refrain from any speciﬁc diet during the study
period.
2.3. Body Composition and Indirect Calorimetry. Body com-
position was measured using bioelectrical impedance anal-
ysis (Maltron BF-906, Rayleigh, UK). Oxygen consumption
(VO2) and CO2 production (VCO2)w e r em e a s u r e dw i t h
20sec intervals for a total time of 30min by indirect
calorimetry using a ventilated hood system (Sensormedic-
smodel 2900; Sensormedics, Anaheim, Calif, USA). Patients
were studied in the morning after an overnight fast. Dur-
ing and 30min prior to the calorimetry measurements,
subjects were instructed to rest in the supine position in
a temperature-controlled room (23◦C). REE, lipid, and
glucose oxidation were calculated from VO2 and VCO2
values using algorithms previously reported by Frayn [9].
Respiratory quotient (RQ) was calculated as VCO2/VO2.
The ﬁnal 25min of each calorimetry measurement, during
which stable VO2 and VCO2 values are reached, was
averaged for further analysis in every individual patient.
2.4. Hormones. Serum T3 (total), T4 (total), and rT3 were
measured with in-house radioimmunoassay (RIA) [10].
Serum FT4,F T 3, and TSH were measured by time-resolved
ﬂuoroimmunoassay (Delﬁa, Wallac Oy, Turku, Finland).
For FT4 the intra-assay variation was 4-5%, the inter-assay
variation 6-7%, and the detection limit 2pmol/L. For FT3
the intra-assay variation was ±6%, the inter-assay variation
±9%, and the detection limit 1pmol/L. For TSH the intra-
assayvariationwas3-4%,theinter-assayvariation4-5%,and
the detection limit 0.01mU/L. Insulin was measured with
a chemiluminescent immunometric assay (Immulite 2000
system,DiagnosticProductsCorporation,LosAngeles,Calif,
USA) with an intra-assay variation of 3–6%, an inter-assay
variationof4–6%,andadetectionlimitof15pmol/L.Serum
TBII was quantitatively determined by a second-generation
luminescence receptor assay (DYNOtest TRAK human assay,
B.R.A.H.M.S.).Noradrenalinandadrenalinweredetermined
with an in-house HPLC method. Intra-assay variation for
noradrenalin: 2% and adrenalin 9%; inter-assay variation forInternational Journal of Endocrinology 3
Table 1: Anthropometric characteristics of subjects (n = 22; 19
females, 4 males).
Median Min.–Max.
Age (yr) 45.5 24–56
Weight (kg) 67.5 49.4–106.6
Height (cm) 168 158–182
BMI (kg/m2) 23.8 19.9–35.8
Lean body mass (%) 69.6 52.0–80.7
Fat mass (%) 30.4 19.3–48.0
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Figure 1: Serum FT3/FT4 ratios of 22 euthyroid Graves patients
during BRT (visit 1; grey boxplots) and 12 weeks after cessation of
BRT (visit 2, open boxplots). ∗P = 0.007, visit 1 versus visit 2.
noradrenalin: 10% and adrenalin: 14–18%; detection limit
was 0.05nmol/L for both hormones.
2.5. Statistics. All data were analyzed using nonparametric
tests. We performed comparisons between study occasions
with the Wilcoxon Signed Rank test and expressed corre-
lations as Spearman’s rank correlation coeﬃcient (r). SPSS
statistical software version 12.0.1 (SPSS Inc, Chicago, Ill,
USA) was used for statistical analysis. Data are presented as
median (minimum-maximum).
3. Results
Thirty-nine biochemically euthyroid patients were initially
included and studied before cessation of BRT. Of these
patients, nine had developed a relapse of hyperthyroidism
while two patients who had undergone radio-iodine (I131)
ablationtherapyhaddevelopedhypothyroidismatvisit2.Six
patients were excluded from the ﬁnal analysis on the basis of
serum FT4 or T3 values outside the reference range, or serum
TSH values above the upper limit of the reference range.
Thus, the ﬁnal analysis was performed in 22 patients who
were biochemically euthyroid at both visits.
3.1. Anthropometric Characteristics. Baseline anthropomet-
ric characteristics are depicted in Table 1. Out of 22 patients,
2 patients (9%) smoked. These patients were instructed not
to smoke 12 hours prior to measurements and not to change
their smoking habits between study visits.
3.2. Body Weight and Energy Homeostasis. Patients reported
that before the onset of the symptoms—later attributed
to hyperthyroidism—that had urged them to seek medi-
cal advice, BW, that is, premorbid BW, was 64.0 (47.5–
97.0)kg.Eighty-twopercent(18/22)ofpatientsreportedthat
decreasedBWwasamongthesymptomsofhyperthyroidism.
At the time of diagnosis of hyperthyroidism, the patients
had lost 4.8 (0.0–25.0)kg of self-reported premorbid BW.
Nineteen patients were started on methimazole, and 3
patients were started on PTU, to which thyroxine was added
as soon as biochemical euthyroidism was reached. At visit 1,
when BRT was discontinued, patients had been treated with
BRTfor13.5(9.5–48.0)months.DuringBRTpatientsgained
6.9 (−0.1–14.6)kg. The diﬀerence between premorbid BW
and BW at visit 1 (i.e., presumed weight gain) was 2.4
(−17.1–14.6)kg (premorbid BW versus visit 1 BW, P =
0.001).
There was no signiﬁcant diﬀerence in median BW
between visit 1 and visit 2, 12weeks after cessation of BRT
(Table 1, P = 0.899). The median diﬀerence in BW between
visit 1 and visit 2 calculated per individual patient was 0.0
(−5.4–3.2)kg. Furthermore, there was no diﬀerence in REE,
fat and glucose oxidation, RQ, or body fat mass between visit
1 and visit 2 (Table 2).
3.3. Hormones. Serum T4 and FT4 were not diﬀerent
between visit 1 and 2 (P = 0.362 and P = 0.676,
resp., Table 3). Serum T3 tended to increase at visit 2 as
compared with visit 1 (3%, P = 0.069), whereas FT3
showed a statistically signiﬁcant increase at visit 2 (20%,
P = 0.005). Serum TSH levels decreased by 59% and serum
TBII concentrations by 15% at visit 2 compared with visit 1
(P = 0.001 and P = 0.007, resp.). Accordingly, the serum
T3/T4 ratio increased by 10% from 1.79% (visit 1) to 1.97%
(visit 2, P = 0.033), and the serum FT3/FT4 ratio increased
by 16% from 31.8% (visit 1) to 37.0% (visit 2, P = 0.007, see
Figure 1).
At visit 1, there was a positive correlation between serum
FT4 and REE (P = 0.044, Figure 2(a))a n dan e g a t i v e
correlation between serum FT4 and % body fat mass (P =
0.035,Figure 2(b)).Inaddition,therewasahighlysigniﬁcant
negative correlation between REE and % body fat mass
(r =− 0.549, P = 0.008). Serum FT3 tended to correlate
positively with REE (P = 0.066, Figure 2(c)), but showed no
correlation with % body fat mass (P = 0.288, Figure 2(d)).
However, at visit 2, these signiﬁcant correlations were
absent (FT4 versus body fat % r =− 0.247, P = 0.270,
FT4 versus REE r = 0.320, P = 0.172, FT3 versus body
fat % r =− 0.109, P = 0.630, FT3 versus REE, r = 0.135,
P = 0.550). Intriguingly, the diﬀerence in (Δ)F T 3/FT4 ratio
and ΔREE between visit 1 and visit 2 showed a positive
correlation (r = 0.465, P = 0.029, see Figure 3).
There were no diﬀerences in serum glucose, insulin,
adrenalin, or noradrenalin between the two visits (Table 3).4 International Journal of Endocrinology
Table 2: Body weight (BW).
Median Min.–Max. P
kg kg
Premorbid BW (self reported) 64.0 a 47.5–97.0
BW at diagnosis GD 62.0 b 45.0–92.0 <0.0001 (a versus b)
BW visit 1 (during BRT) 68.1 c 49.4–106.6 <0.0001 (b versus c)
BW visit 2 (12w after BRT cessation) 67.1 d 48.0–106.5 0.889 (c versus d)
Median
kg %
Δ BW (visit 1–premorbid) 2.4 3.7 −17.1–14.6
Δ BW (visit 1–visit 2) 0.0% 0.0% −5.4–3.2
Table 3: REE, substrate oxidation, and body composition.
Visit 1 Visit 2 P
Median Min.–Max. Median Min.–Max.
REE (kCal/kg∗24h) 19.7 14.3–24.3 20.3 13.2–26.2 0.249
Body fat mass (% of total BW) 30.4 19.3–48.0 29.1 19.6–49.8 0.102
RQ 0.81 0.74–0.92 0.81 0.72–0.91 0.910
Glucose oxidation (mg/min∗kg) 1.12 0.17–2.23 1.26 0.00–2.22 0.745
Lipid oxidation (mg/min∗kg) 0.75 0.15–1.23 0.71 0.20–1.11 0.858
4. Discussion
Patients with Graves disease who are treated with a combina-
tion of a thyreostatic drug and thyroxine replacement, that
is, block and replacement therapy (BRT), often experience a
marked gain in BW [3], which has been reported to exceed
self-reported premorbid BW [4]. However, there are some
inconsistencies in the published data on this issue. In the
present study, we found a median weight excess of 2.4kg
compared with self-reported premorbid BW in a group
of 22 euthyroid patients with Graves hyperthyroidism who
had been treated with BRT for a median of 13.5 months.
To further investigate this phenomenon we assessed energy
homeostasis and serum hormone concentrations in these
patients both before and 12 weeks after cessation of BRT.
Somewhat unexpectedly, patients showed no change in BW
or REE at 12 weeks after BRT cessation.
With respect to the 2.4kg BW excess, we are aware
of the uncertainty regarding the reliability of self-reported
premorbid BW [11]. Symptoms such as a decrease in BW are
slowlyprogressiveandpatientsmayﬁndithardtoremember
the precise onset of symptoms. Therefore, we cannot exclude
that underestimation of the self-reported premorbid BWs
may have led to an overestimation of the BW excess during
BRT in our patients. In any case, the present study does not
supporttheclinicalimpressionofamarkedandexcessiveBW
increase after ∼1 year of BRT following hyperthyroidism.
Hyperthyroidism is associated with a marked increase
in REE [12, 13]. The simultaneous increase in appetite and
caloric intake does not completely prevent weight loss in
most hyperthyroid patients [14]. By inference, BW changes
appear to be primarily determined by EE in these patients.
In addition, it has been shown previously that caloric intake
decreases rapidly to normal within 3 months of initiation
of antithyroid treatment, whereas in the same period BW
increases to premorbid levels [1]. Therefore, increased
caloric intake is not a likely candidate to explain the BW
gain after initiation of thyreostatic treatment. Our ﬁnding
that REE and BW are similar during treatment with BRT
compared with 12 weeks after BRT cessation suggests that
BRT does not induce a major change in energy homeostasis
and, in turn, BW gain in excess of the premorbid situation.
The patients in our study were euthyroid on both
occasions, following the design of the study. This enabled
us to investigate the relationship between subtle changes in
serum TH values within the euthyroid range on the one
hand and measures of energy homeostasis on the other
hand. As anticipated, serum FT3/FT4 ratios signiﬁcantly
(16%) increased after cessation of BRT. This can probably be
attributed to reinstated thyroidal T3 secretion, whereas enzy-
matic conversion from exogenous T4 is probably the major
source of serum T3 during BRT. Interestingly, there was a
signiﬁcant and positive correlation between the diﬀerence in
serum FT3/FT4 ratio and the diﬀerence in REE between the
2 study occasions, suggesting that the serum FT3/FT4 ratio
is a positive determinant of REE under these circumstances
(Figure 3).Inaddition,serumFT4 levelswithintheeuthyroid
range were a positive determinant of REE. Also FT3 tended
to positively determine REE. This illustrates the sensitivity
of REE to even small ﬂuctuations in circulating thyroid
hormone concentrations, which is supported by previous
reports [15, 16]. As anticipated, REE and % body fat mass
showed a highly signiﬁcant negative correlation. Therefore,
it is likely that the negative correlation between serum FT4
and % body fat mass can be explained by the observation
that FT4 positively determines REE. It appears remarkable
that these correlations reached statistical signiﬁcance despite
therelativelysmallnumber and heterogeneity(i.e.,regardingInternational Journal of Endocrinology 5
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Figure 2: Correlations of serum FT4 with resting energy expenditure (REE, (a)) and body fat mass (b), and serum FT3 with REE (c) and
body fat mass (d). Spearman’s correlation coeﬃcients (r)a n dP values are plotted under the horizontal axis of each graph.
age, sex, BMI, body fat mass) of patients. Why this was only
evident during BRT treatment and not at visit 2 remains
unclear. It may be that after cessation of BRT, the patho-
physiologicalchangesintheHPT-axisassociatedwithGraves
disease (e.g., by circulating TBII) prevent the detection of
clear-cut associations between circulating thyroid hormones
and REE. Another explanation may be that a period of
1 2w e e k si sn o ts u ﬃcient to reinstate physiological thyroid
hormone synthesis and release from the thyroid gland.
Although REE and BW were unaltered 12w after BRT
cessation, the data presented do raise a number of interesting
possibilities. Our ﬁnding that changes in serum FT3/FT4
ratios positively determine REE in euthyroid patients
(Figure 3) suggests that tissues capable of modulating energy
metabolism sense even small changes in circulating THs
and alter REE accordingly. Candidates include tissues sig-
niﬁcantly contributing to REE and expressing TH receptors
such as the heart and CNS, while striated muscle and
adipose tissue maycontributetoalesserextent [17].Another
possibility to explain these ﬁndings may be TH-dependent
regulation of REE via the brain, as the hypothalamus plays a
major role in the regulation of energy metabolism [18, 19].
Interestingly, there is a high density of TH receptors in the
rat and human hypothalamic arcuate and paraventricular
nuclei [20, 21], and these nuclei are both key players in BW
regulation [16]. Recently, we have shown that hypothalamic
T3 administration stimulates hepatic glucose production via
aneuralpathwayinvolvingthehypothalamicparaventricular
nucleus and the sympathetic nervous system [22]. Thus, the
hypothalamus is able to sense THs and in turn modulate
hepatic glucose metabolism by means of altered sympathetic
outﬂow to the liver. This raises the possibility that it
may similarly modulate energy metabolism by autonomic
projections to other target tissues such as skeletal muscle and
adipose tissue in response to TH [23, 24].
Serum TSH concentration was lower at visit 2 as
compared with visit 1, although it remained within refer-
ence intervals. This may be explained either by subtle T46 International Journal of Endocrinology
Table 4: Plasma hormone concentrations at visit 1 and visit 2.
Visit 1 Visit 2 P Reference range
Median Min.–max. Median Min.–max.
T4 (nmol/L) 95 60–170 90 70–130 0.362 70–150
FT4 (pmol/L) 13.7 10.0–19.3 14.0 10.5–21.3 0.676 10.0–23.0
T3 (nmol/L) 1.68 1.2–2.3 1.73 1.3–2.7 0.069 1.3–2.7
FT3 (pmol/L) 4.4 3.0–6.2 5.3 3.9–9.3 0.005 3.3–8.2
TSH (mU/L) 1.70 0.04–4.50 0.70 0.01–2.03 0.001 0.5–5.00
TBII (U/L) 1.3 0.5–8.9 1.1 0.5–7.6 0.007
Insulin (pmol/L) 30 15–131 32 15–136 0.695 34–172
Adrenalin (nmol/L) 0.08 0.05–0.48 0.09 0.05–0.51 0.872 0.00–0.55
Noradrenalin (nmol/L) 1.05 0.43–3.69 1.38 0.53–4.18 0.833 0.00–3.25
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Figure 3: Correlation of the diﬀerence in REE corrected for BW
between visit 1 and visit 2 (Δ REE (%)) and the diﬀerence in
serum FT3/FT4 ratios between visit 1 and visit 2 (Δ FT3/FT4 (%)).
Spearman’s correlation coeﬃcient (r) = 0.465, P = 0.029.
under-treatmentduringBRTdespiteserumT4 andFT4 levels
within the reference range. Alternatively, the decrease in
serum TSH may point to a tendency to develop a relapse
of hyperthyroidism in some patients. However, this latter
possibility appears to be less likely given the decrease of
serum TBII, 12w after BRT cessation Table 4.
In conclusion, we observed no changes in BW and
resting energy metabolism 12 weeks after cessation of BRT
in euthyroid Graves patients, so the present ﬁndings do
not support the notion that BRT per se induces excessive
BW gain. However, patients who stopped BRT showed an
increase in the serum FT3/FT4 ratio, and these changes in
FT3/FT4 ratio were a positive determinant of changes in
REE. Hence, it is well possible that the changes in circulating
thyroid hormones after cessation of BRT require a longer
observational period in order to translate into clear-cut
alterations in BW.
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